Based in New York, Thompson Dean engages as Co-CEO of Avista Capital Partners and oversees the firm’s middle-market growth investment and buyout strategies in health care markets. Thompson Dean’s firm has taken a position in the regenerative-medicine firm Organogenesis Holdings, Inc., which focuses on products in surgical and sports medicine and advanced wound care.
A recent Plastic and Reconstructive Surgery – Global Open case series confirmed the efficacy of Organogenesis’ PuraPly Antimicrobial (PuraPly AM) product in enabling healing in chronic, complex wounds that had previously been unresponsive to treatment.
Encompassing 41 studied wounds, the findings were that nearly three-fourths of wounds demonstrated significant area reduction within a 12-week period.
Over a mean time of less than seven weeks, 37 percent of the wounds completely closed, a prerequisite to full healing. This clinical experience provides evidence that PuraPly AM, when used appropriately, can improve the outcomes of patients who previously lived with debilitating medical issues related to wounds.
A recent Plastic and Reconstructive Surgery – Global Open case series confirmed the efficacy of Organogenesis’ PuraPly Antimicrobial (PuraPly AM) product in enabling healing in chronic, complex wounds that had previously been unresponsive to treatment.
Encompassing 41 studied wounds, the findings were that nearly three-fourths of wounds demonstrated significant area reduction within a 12-week period.
Over a mean time of less than seven weeks, 37 percent of the wounds completely closed, a prerequisite to full healing. This clinical experience provides evidence that PuraPly AM, when used appropriately, can improve the outcomes of patients who previously lived with debilitating medical issues related to wounds.
